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The childhood neuronal ceroid lipofuscinoses (NCLs) are inherited neurodegenerative diseases that are progressive and ultimately
fatal. An Australian Shepherd that exhibited a progressive neurological disorder with signs similar to human NCL was
evaluated. The cerebral cortex, cerebellum, and retina were found to contain massive accumulations of autoﬂuorescent inclusions
characteristic of the NCLs. Nucleotide sequence analysis of DNA from the aﬀected dog identiﬁed a T to C variant (c.829T>C) in
exon 7 of CLN6. Mutations in the human ortholog underlie a late-infantile form of NCL in humans.The T-to-C transition results
in a tryptophan to arginine amino acid change in the predicted protein sequence. Tryptophans occur at homologous positions
in the CLN6 proteins from all 13 other vertebrates evaluated. The c.829T>C transition is a strong candidate for the causative
mutation in this NCL-aﬀected dog. Dogs with this mutation could serve as a model for the analogous human disorder.
1.Introduction
The neuronal ceroid lipofuscinoses (NCLs) are inherited
neurodegenerative disorders that occur in humans and a
numberofothermammals, includingdogs,cats,sheep,mice,
and cattle [1, 2]. In most NCLs, the development of the
nervous system appears to occur normally, but starting at
various ages, progressive neurodegeneration leads to symp-
tomsthatcanincludevisionloss, behaviorchanges,cognitive
and motordecline,seizures, and premature death.The NCLs
are distinguished from other inherited neurodegenerative
disorders by the accumulation of autoﬂuorescent lysosomal
storage granules in neurons and other cell types, both within
and outside the central nervous system.
NCLshavebeenreportedinalargenumberofdogbreeds
including Border Collies, English Setters, American Bull-
dogs, Dachshunds, Polish Lowland Sheepdogs, and Tibetan
Terriers [3]. For many breeds, NCLs have been reported as
isolated cases and no genetic analyses have been undertaken.
However, for ﬁve breeds (Border Collies, English Setters,
American Bulldogs, Dachshunds, and Tibetan Terriers), the
causative mutations have been identiﬁed, all of which are
associated with an autosomal recessive mode of inheritance.
These mutations all occur in orthologs of genes that contain
mutations responsible for speciﬁc forms of human NCL or
a similar disorder. We previously identiﬁed NCL in a family
of Australian Shepherds[4]. Only paraﬃn-embedded tissues
were available from these dogs, and no genetic analyses
were undertaken. Formalin-ﬁxed tissues were obtained from
an unrelated Australian Shepherd that was euthanized after
exhibiting similar symptoms. Ultrastructural examination of
the storage materials in brain samples suggested that the
disease in this dog might result from a CLN6 mutation.
Therefore, genomicDNAwas recovered from paraﬃn blocks
from the dog’s tissues and analyzed to determine whether
CLN6 contained any potential disease-causing mutations.2 Journal of Biomedicine and Biotechnology
Table 1: PCR primer sequences used for analysis of canine the CLN6 gene.
Target Forward primer/reverse primer Amplicon size (bp)
Exon 1 CCGTTCGTGCTTCCCGCAAC/GGACGCGCGGTGGATGGAC 288
Exon 2 TCGAGTCCCCATACCTTTCTG/CACTGCTGGTAAGGGCTCTGTC 245
Exon 3 TTCTGGGCCTGGGTGAACAC/CTGCTTCCACTGGCCTCCATGA 243
Exon 4 GAGCCACGGCCTCCCTC/GACGGCCCGACCCACAA 267
Exon 5 TGGAGGCGCCCTGCTG/TGCGCGCTGCCCTCTAGT 281
Exon 6 CAGGACGGCTGGTGCAAG/CCAGGGCACGCACGTTT 281
Exon 7 (5) GTGGGTACAGCGAGGGATGCC/CCGGGTACTTCTTCCTGAGC 285
Exon 7 (3) CTTCGCTCTCACCCTCCTGCT/GCCGTGATGACCGCACA 249
2.Materialsand Methods
A pet female Australian Shepherd began to exhibit decreased
vision around the age of 18 months, and by 19 months this
had progressed to complete blindness. At the same time the
dog began to exhibit signs of anxiety, circling behavior, and
loss of coordination that became progressively worse. The
anxiety progressed as well, and she became very startled
and anxious when touched or exposed to loud and sudden
sounds. Ultimately her anxiety made her unwilling to go
outside. She lost her ability to respond appropriately to her
owners’voices.Eventually,itbecamediﬃcultforhertolocate
her food or water dishes, and when she did, her lack of
head coordination made it diﬃcult for her to eat or drink.
The dog was euthanized at 24 months of age, and the body
was submitted to the Tennessee Department of Agriculture
for pathological analysis. Gross examination of the brain
revealed enlarged lateral ventricles and apparent hypoplasia
ofthecerebellum.Formalin-ﬁxedsamplesofbrainandretina
were sent to us for analysis.
Pieces of the ﬁxed tissues were washed in 0.17M
sodium cacodylate, pH 7.4, embeddedin Tissue Tek (Sakura,
Torrance, CA), and frozen. Sections of the tissue were cut
at a thickness of 5μm with a cryostat and mounted on
glass slides. The sections were covered with 0.17M sodium
cacodylate. Coverslips were placed over them and attached
to the slides at the edges with adhesive. The sections were
then examined and photographed with a Zeiss Axiophot
microscope equipped for epiﬂuorescence illumination [5].
Additional pieces of the tissues were washed in 0.17M
sodium cacodylate, pH 7.4, and were then incubated with
gentle agitation in a mixed aldehyde ﬁxative [6]f o ra
minimum of 24 hours. The samples were then processed for
examination with transmission electron microscopy using a
microwave-assisted technique [6]. Sections were examined
with a JEOL 1400 transmission electron microscope.
Twenty sections were cut at a thickness of 20μm
from a paraﬃn-embedded block of cerebral cortex from
the NCL-aﬀected Australian Shepherd. The sections were
pooled, deparaﬃnized, and rehydrated. Genomic DNA was
extracted from the rehydrated tissue as previously described
[5, 7]. The same procedure was used to extract DNA
from a paraﬃn block containing tissue from an unre-
latedNCL-aﬀectedAustralianShepherddescribedpreviously
in [4]. Additional canine DNA samples were obtained
from the University of Missouri Canine DNA Repository
(http://www.caninegeneticdiseases.net/).Thesesampleswere
extracted from the blood of donor dogs that had not
exhibited signs of NCL.
Oligo software (version 6.70) and sequences from
build 2.1 of the canine genome reference sequence (http://
www.ncbi.nlm.nih.gov/projects/mapview/map searchcgi?
taxid=9615) were used to design PCR primers ﬂanking
the coding regions in each of the seven canine CLN6
exons (Table 1) .E x o n s2 ,3 ,a n d5t o7w e r ea m p l i ﬁ e d
as previously described [7]; however, because of their
high GC content, exon 1 and 4 were ampliﬁed with
AccuPrime GC-Rich DNA Polymerase (Invitrogen). Puriﬁed
PCR ampliﬁcation products were sequenced with an
Applied Biosystems 3730xl DNA analyzer. A TaqMan allelic
discrimination assay was used to genotype the dogs at the
putative disease locus described below. The PCR primer
sequences were 5-CCTCTTCTACTCCTTCGCTCTCA-
3 and 5-ACACCCGGGTACTTCTTCCT-3 and the
competing ﬂuorescent labeled probe sequences were 5-
VIC-CAGGCGACCCGCAGG-MGB-3 (mutant) and 5-
FAM-CAGGCGACCCACAGG-MGB-3 (wild type).
3.Results
Fluorescence microscopic examination of unstained tissue
sections revealed the presence of massive amounts of aut-
oﬂuorescent material in the cerebral cortex, cerebellum,
and retina of the aﬀected dog (Figure 1). This material
was widely distributed throughout the cerebral cortex, but
occurred most predominantly in the Purkinje and granular
layers of the cerebellum. Autoﬂuorescence in the retina
occurred primarily in the ganglion cell layer (Figure 1). The
ultrastructure of the storage bodies from each of the tissues
appeared as membrane-bound inclusions ﬁlled with tightly
packed vesicular and membranous structures (Figure 2).
Using the primers in Table 1,w ew e r ea b l et oa m p l i f y
all seven CLN6 exons with template DNA from blood from
control dogs. Nonetheless, we were only able to amplify
CLN6 exons 2, 3, 5, 6, and 7 (but not exons 1 and 4)
from the DNA recovered from paraﬃn blocks containing
tissue from the aﬀected Australian Shepherd. A comparison
of the sequences of the ampliﬁed exons from the aﬀected
dog with corresponding sequences from a clinically normal
Australian Shepherd and with sequences in the canineJournal of Biomedicine and Biotechnology 3
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Figure 1: Fluorescence micrographs of the ganglion cell layer of the retina (a), cerebral cortex (b), and cerebellum (c) from the Australian
Shepherd that was euthanized after exhibiting the neurological signs described in the text. In the cerebellum, autoﬂuorescent material was
most prominent in the Purkinje cell (p) and granular layers (g), with lesser accumulation in the molecular layer (m). Bar in (a) indicates
magniﬁcation of all 3 micrographs.
genome reference sequence Build 2.1 (http://www.ncbi.nlm
.nih.gov/projects/mapview/map search.cgi?taxid=9615)r e -
vealed two sequence variants: a c.668+7G>A polymorphism
in intron 6 and a c.829T>C transition in exon 7 (Figure 3).
The latter sequence change results in a missense mutation
that predicts a p.W277R mutation in the canine CLN6
protein. Comparison of the predicted amino acid sequence
of the aﬀected dog with those of 13 other vertebrate species
including mammals, birds, ﬁsh, and amphibians indicated
that tryptophan was conserved at the equivalent site in all
other vetebrates with available sequences (Figure 4(a)).
We used a TaqMan allelic discrimination assay, designed
to distinguish wild-type homozygotes, heterozygotes, and
mutant homozygotes, to genotype DNA samples from the
NCL-aﬀected Australian Shepherd, 637 healthy unrelated
Australian Shepherds, and 43 dogs of other breeds from the
University of Missouri Canine DNA Repository. The aﬀected
Australian Shepherd was homozygous for the C allele, but
all of the other genotyped dogs were homozygous for the T
allele. We were also able to genotype one of the Australian
ShepherdspreviouslyreportedtohavesuﬀeredfromNCL[4]
using DNA recovered from paraﬃns e c t i o n s .T h i sa ﬀected
Australian was also homozygous for the wild-type T allele.
4.Discussion
The clinical history and histopathologic ﬁndings conﬁrm
that the subject of this paper was aﬀected with NCL. Of the
NCLs, the ultrastructural appearance of the brain storage
material most closely resembled that of storage bodies that
accumulatein the brain as a result of mutations in CLN6 [8].
Therefore, this gene was analyzed for mutations that might
underlie the NCL of the Australian Shepherd. While we
cannotdrawdeﬁnitiveconclusionsaboutthegeneticcauseof
1μm
Figure 2: Electron micrograph of storage bodies from the cerebel-
lum of the aﬀected Australian Shepherd.
the disease based solely on DNA from a single dog,
the c.829T>C transition constitutes a missense mutation
producing a CGG arginine codon instead of the common
TGG codon for tryptophan. Because all vertebrate CLN6
sequences available in GenBank and CLN6 sequences of
hundreds of unaﬀected dogs have a tryptophan at the
corresponding position, this exon 7 mutation is a likely
candidate for causing NCL in this Australian Shepherd.
CLN6 is predicted to be an intrinsic membrane protein
with 7 transmembrane domains [9]. Based on the pre-
dicted topology, the p.W277R mutation would lie within
the membrane-spanning region of the 7th transmembrane
domain. Five missense mutations encoding a single amino4 Journal of Biomedicine and Biotechnology
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Figure 3: Partial nucleotide sequence of exon 7 of CLN6 in a normal dog and in the aﬀected Australian Shepherd illustrating the c.829T>C
mutation.
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Figure 4: (a) Partial amino acid sequences of CLN6 from a number of species showinguniqueness of the p.W277R mutation in the aﬀected
Australian Shepherd. (b) Partial amino acid sequence of human CLN6 showing missense mutation sites (shaded: p.M241T1; p.R252H2;
pG259C3; p.P299L5; p.W300R6) that result in human vLINCL and the amino acid corresponding to the Australian Shepherd mutation
(underlined: p.W277R4).
acid change have been documented in human patients
for this region of CLN6 (Figure 4(b)), all of which cause
the same variant form of late infantile NCL (vLINCL)
(http://www.ucl.ac.uk/ncl/cln6.shtml). Because the function
of CLN6 is currently unknown [10], it is not possible to
predict what eﬀects this mutation might have on cellular
metabolism or to determine whether the mutation results in
functional alterations.
Our inability to amplify and sequence exons 1 and 4
of CLN6 from the aﬀected Australian Shepherd could be
attributable to partial degradation of the DNA recovered
from formalin-ﬁxed tissue. However, the possibility that
these exons contain additional sequence variants cannot
be ruled out. The c.668+7G>A polymorphism in Intron 6
is unlikely to be the cause of the disease as it is beyond
the consensus sequence for exon splice donor recognition
[11].
Unfortunately, pedigree information from the aﬀected
Australian shepherd was unavailable and closely related dogs
could not be located, so we were unable to genotype otherJournal of Biomedicine and Biotechnology 5
dogs from the same family. We failed to identify additional
dogs carrying the mutant allele even though we screened
680dogsincluding637 AustralianShepherds.The onlyother
published report of NCL in Australian Shepherds described
NCL in three littermates with ages at onset and general
patterns of symptoms that were very similar to that of the
Australian Shepherd described above [4]. We extracted DNA
from a paraﬃn block containing brain tissue from one of
the aﬀected littermates and determined that the dog was
homozygous for the wild-type T allele. This suggests that
two distinct forms of NCL have occurred among Australian
Shepherds. Consistent with this possibility, the pattern of
autoﬂuorescent storage material in the cerebellum was quite
diﬀerentbetween the current dog and the aﬀected Australian
Shepherd littermates that were previously described. In the
currently described Australian Shepherd, the vast majority
of the storage material was present in the granular cell layer,
whereas in the previous cases the storage material occurred
primarily in the Purkinje cells (cf. Figures 2 and 5)[ 4]. In
addition,therewere distinct diﬀerencesintheultrastructural
appearance ofthestorage bodiesbetweenthe dogwith CLN6
mutation and those of the Australian Shepherds previously
described with NCL [4]. Whereas in the present case the
storage bodies appeared to be aggregates of membranous
vesicles (Figure 2), the brain storage bodies in the previous
cases consisted primarily of aggregates of multilayered mem-
branous whorls [4]. In the Australian Shepherd evaluated
in this study the ultrastructural appearance of the storage
material was quite similar to that of storage material from
the brains of sheep that have been shown to suﬀer from
NCL as a result of a mutation aﬀecting CLN6 expression
[8, 12, 13].
T h eo c c u r r e n c eo fm o r et h a no n ef o r mo fN C Lw i t h i n
a single breed is not surprising. We have identiﬁed two
mutations responsible for NCL in Dachshunds [7, 14], as
well as additional Dachshunds with NCL that have neitherof
these mutations. Likewise, similar disease phenotypes occur
inhumanswithmutationsindiﬀerentgenesthatleadtoNCL
[15, 16]. For a number of the human NCLs, it was not until
thecausativemutationswereidentiﬁedthatitwasrecognized
that many cases of NCL with similar symptoms and ages of
onset actually represent diﬀerent genetic defects. With the
discoveryofatleasteightdiﬀerentNCLgenes,severalhuman
NCLs that were previously classiﬁed together have now been
shown to be genetically distinct. Therefore, even within a
dog breed, the failure to detect a known NCL mutation is
not suﬃcient to rule out NCL as the cause of progressive
neurological deterioration.
Among Australian Shepherds, the frequency of the
c.829T>C allele appears to be very low, based on our
surveyof unaﬀectedrepresentativesofthebreed.Further, the
paucity of published reports suggests that NCL is rare in the
breed.Thus,widespreadtestingfortheCLN6 mutationisnot
presently warranted with respect to eliminating a potential
health problem in the breed. However, given that symptom
onsetofbothformsofNCLinthisbreedislessthan2years,it
wouldbewise forbreederstomonitorany dogstheyproduce
for signs of the disease for their ﬁrst 2 years. If potentially
m
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Figure 5: Fluorescence micrograph of the cerebellum from an
Australian Shepherd with NCL that tested homozygous for the T
allele at the c.829 locus [4]. The layers of the cerebellum are labeled
a sf o l l o w s :g :g r a n u l a rl a y e r ;p :P u r k i n j el a y e r ;m :m o l e c u l a rl a y e r .
aﬀected dogs are identiﬁed, the aﬀe c t e dd o g sa sw e l la st h e
parents and other dogs closely related to the aﬀected animals
should be tested for the mutant allele. If living sexually
intact dogs that are heterozygous for the CLN6 mutation can
be located, they could be used for breeding to establish a
research colony. Locating such dogs could be accomplished
by screening large numbers of Australian Shepherds for the
mutation using the allelic discrimination assay.
5.Conclusions
Australian Shepherds with the identiﬁed CLN6 mutation
would bea valuablemodel forelucidatingthefunction ofthe
CLN6 protein and the mechanisms by which mutations in
CLN6 result in NCL disease pathology. Such dogs would be
useful for evaluating potential therapies for the correspond-
ing human disease. Using an allelic discrimination assay, we
should be able to identify those rare Australian Shepherds
that carry the mutation for use in establishing a canine
model.
We recently identiﬁed a living Australian shaped exhibit-
ing clinical signs similar to those displayed by the dog
described in this study. The living dog is homozygousfor the
C allele at c.829.
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